Entera Bio Net Income
| ENTX Stock | USD 1.51 0.00 0.00% |
As of the 16th of February 2026, Entera Bio shows the Standard Deviation of 6.24, mean deviation of 4.25, and Variance of 38.94. Entera Bio technical analysis allows you to utilize historical prices and volume patterns in order to determine a pattern that computes the direction of the firm's future prices.
Entera Bio Total Revenue |
|
Market Capitalization | Enterprise Value Revenue 489.1302 | Revenue | Earnings Share (0.24) | Quarterly Revenue Growth (0.92) |
| Last Reported | Projected for Next Year | ||
| Net Loss | -8.6 M | -9 M | |
| Net Loss | -11.8 M | -12.4 M | |
| Net Loss | -8.6 M | -9 M | |
| Net Loss | (0.23) | (0.24) | |
| Net Income Per E B T | 0.90 | 0.80 |
Entera | Net Income | Build AI portfolio with Entera Stock |
The evolution of Net Income for Entera Bio provides essential context for understanding the company's financial health trajectory. By analyzing this metric's behavior over time, investors can assess whether recent trends align with long-term patterns, and how Entera Bio compares to historical norms and industry peers.
Latest Entera Bio's Net Income Growth Pattern
Below is the plot of the Net Income of Entera Bio over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Entera Bio financial statement analysis. It represents the amount of money remaining after all of Entera Bio operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Entera Bio's Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Entera Bio's overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (9.54 M) | 10 Years Trend |
|
Net Income |
| Timeline |
Entera Net Income Regression Statistics
| Arithmetic Mean | (7,674,185) | |
| Coefficient Of Variation | (46.35) | |
| Mean Deviation | 3,156,270 | |
| Median | (8,889,000) | |
| Standard Deviation | 3,557,139 | |
| Sample Variance | 12.7T | |
| Range | 11.9M | |
| R-Value | (0.69) | |
| Mean Square Error | 7T | |
| R-Squared | 0.48 | |
| Significance | 0 | |
| Slope | (486,849) | |
| Total Sum of Squares | 202.5T |
Entera Net Income History
Other Fundumenentals of Entera Bio
| Net Income From Continuing Ops | ||
| Net Income Applicable To Common Shares | ||
| Net Income Per Share | ||
| Net Income Per E B T |
Entera Bio Net Income component correlations
Entera Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Entera Bio is extremely important. It helps to project a fair market value of Entera Stock properly, considering its historical fundamentals such as Net Income. Since Entera Bio's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Entera Bio's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Entera Bio's interrelated accounts and indicators.
Click cells to compare fundamentals
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Entera Bio. Projected growth potential of Entera fundamentally drives upward valuation adjustments. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Entera Bio assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Earnings Share (0.24) | Revenue Per Share | Quarterly Revenue Growth (0.92) | Return On Assets | Return On Equity |
The market value of Entera Bio is measured differently than its book value, which is the value of Entera that is recorded on the company's balance sheet. Investors also form their own opinion of Entera Bio's value that differs from its market value or its book value, called intrinsic value, which is Entera Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Entera Bio's market value can be influenced by many factors that don't directly affect Entera Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
It's important to distinguish between Entera Bio's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Entera Bio should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, Entera Bio's quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
Entera Bio 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Entera Bio's stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Entera Bio.
| 11/18/2025 |
| 02/16/2026 |
If you would invest 0.00 in Entera Bio on November 18, 2025 and sell it all today you would earn a total of 0.00 from holding Entera Bio or generate 0.0% return on investment in Entera Bio over 90 days. Entera Bio is related to or competes with Anixa Biosciences, VistaGen Therapeutics, Opus Genetics, Seer, TuHURA Biosciences, Acumen Pharmaceuticals, and Seres Therapeutics. Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally ... More
Entera Bio Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Entera Bio's stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Entera Bio upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.15) | |||
| Maximum Drawdown | 35.2 | |||
| Value At Risk | (8.76) | |||
| Potential Upside | 11.11 |
Entera Bio Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Entera Bio's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Entera Bio's standard deviation. In reality, there are many statistical measures that can use Entera Bio historical prices to predict the future Entera Bio's volatility.| Risk Adjusted Performance | (0.10) | |||
| Jensen Alpha | (0.87) | |||
| Total Risk Alpha | (1.34) | |||
| Treynor Ratio | 8.68 |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Entera Bio's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Entera Bio February 16, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.10) | |||
| Market Risk Adjusted Performance | 8.69 | |||
| Mean Deviation | 4.25 | |||
| Coefficient Of Variation | (723.08) | |||
| Standard Deviation | 6.24 | |||
| Variance | 38.94 | |||
| Information Ratio | (0.15) | |||
| Jensen Alpha | (0.87) | |||
| Total Risk Alpha | (1.34) | |||
| Treynor Ratio | 8.68 | |||
| Maximum Drawdown | 35.2 | |||
| Value At Risk | (8.76) | |||
| Potential Upside | 11.11 | |||
| Skewness | 1.8 | |||
| Kurtosis | 6.17 |
Entera Bio Backtested Returns
Entera Bio secures Sharpe Ratio (or Efficiency) of -0.11, which denotes the company had a -0.11 % return per unit of risk over the last 3 months. Entera Bio exposes twenty-one different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please confirm Entera Bio's Variance of 38.94, standard deviation of 6.24, and Mean Deviation of 4.25 to check the risk estimate we provide. The firm shows a Beta (market volatility) of -0.1, which means not very significant fluctuations relative to the market. As returns on the market increase, returns on owning Entera Bio are expected to decrease at a much lower rate. During the bear market, Entera Bio is likely to outperform the market. At this point, Entera Bio has a negative expected return of -0.7%. Please make sure to confirm Entera Bio's jensen alpha and accumulation distribution , to decide if Entera Bio performance from the past will be repeated at some point in the near future.
Auto-correlation | 0.67 |
Good predictability
Entera Bio has good predictability. Overlapping area represents the amount of predictability between Entera Bio time series from 18th of November 2025 to 2nd of January 2026 and 2nd of January 2026 to 16th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Entera Bio price movement. The serial correlation of 0.67 indicates that around 67.0% of current Entera Bio price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.67 | |
| Spearman Rank Test | 0.49 | |
| Residual Average | 0.0 | |
| Price Variance | 0.03 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Entera Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Entera Bio reported net income of (9.54 Million). This is 102.8% lower than that of the Biotechnology sector and 113.62% lower than that of the Health Care industry. The net income for all United States stocks is 101.67% higher than that of the company.
Entera Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Entera Bio's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Entera Bio could also be used in its relative valuation, which is a method of valuing Entera Bio by comparing valuation metrics of similar companies.Entera Bio is currently under evaluation in net income category among its peers.
Entera Bio Current Valuation Drivers
We derive many important indicators used in calculating different scores of Entera Bio from analyzing Entera Bio's financial statements. These drivers represent accounts that assess Entera Bio's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Entera Bio's important valuation drivers and their relationship over time.
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 (projected) | ||
| Market Cap | 73.7M | 21.0M | 17.4M | 79.8M | 91.8M | 50.0M | |
| Enterprise Value | 49.1M | 8.8M | 6.8M | 71.4M | 82.1M | 41.6M |
Entera Bio Institutional Holders
Institutional Holdings refers to the ownership stake in Entera Bio that is held by large financial organizations, pension funds or endowments. Institutions may hold large blocks of Entera Bio's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Entera Bio's value.| Shares | Geode Capital Management, Llc | 2025-06-30 | 21.1 K | Ubs Group Ag | 2025-06-30 | 15.6 K | Citadel Advisors Llc | 2025-06-30 | 11.7 K | Jane Street Group Llc | 2025-06-30 | 10.2 K | Pnc Financial Services Group Inc | 2025-06-30 | 10 K | Goss Wealth Management Llc | 2025-06-30 | 9 K | Cubist Systematic Strategies, Llc | 2025-06-30 | 815 | Group One Trading, Lp | 2025-06-30 | 51.0 | Perigon Wealth Management, Llc | 2025-06-30 | 0.0 | Knoll Capital Management Lp | 2025-06-30 | 5.9 M | Point72 Asset Management, L.p. | 2025-06-30 | 2.7 M |
Entera Fundamentals
| Return On Equity | -0.99 | ||||
| Return On Asset | -0.54 | ||||
| Operating Margin | (87.29) % | ||||
| Current Valuation | 60.65 M | ||||
| Shares Outstanding | 45.86 M | ||||
| Shares Owned By Insiders | 24.68 % | ||||
| Shares Owned By Institutions | 19.96 % | ||||
| Number Of Shares Shorted | 102.39 K | ||||
| Price To Earning | 2.10 X | ||||
| Price To Book | 4.53 X | ||||
| Price To Sales | 554.72 X | ||||
| Revenue | 181 K | ||||
| EBITDA | (9.54 M) | ||||
| Net Income | (9.54 M) | ||||
| Cash And Equivalents | 17.28 M | ||||
| Cash Per Share | 0.60 X | ||||
| Total Debt | 272 K | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 10.89 X | ||||
| Book Value Per Share | 0.33 X | ||||
| Cash Flow From Operations | (6.82 M) | ||||
| Short Ratio | 0.40 X | ||||
| Earnings Per Share | (0.24) X | ||||
| Target Price | 10.0 | ||||
| Number Of Employees | 20 | ||||
| Beta | 1.84 | ||||
| Market Capitalization | 68.79 M | ||||
| Total Asset | 9.39 M | ||||
| Retained Earnings | (113.93 M) | ||||
| Working Capital | 7.8 M | ||||
| Current Asset | 8.46 M | ||||
| Current Liabilities | 7.64 M | ||||
| Net Asset | 9.39 M |
About Entera Bio Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Entera Bio's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Entera Bio using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Entera Bio based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Entera Stock Analysis
When running Entera Bio's price analysis, check to measure Entera Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Entera Bio is operating at the current time. Most of Entera Bio's value examination focuses on studying past and present price action to predict the probability of Entera Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Entera Bio's price. Additionally, you may evaluate how the addition of Entera Bio to your portfolios can decrease your overall portfolio volatility.